Grothey A, et al. - Authors scrutinized the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) administered for 3 months, as compared with 6 months in patients with stage III colon cancer. Three months of therapy was discovered to be as effective as 6 months, in patients treated with CAPOX, especially in the lower-risk subgroup. It was also determined that among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration.